ReviewNeurology and therapy2026
Current and Emerging Therapies for Pediatric Sleep Disorders: A Narrative Review.
Review in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disorders in children represent a significant public health concern with important implications for neurodevelopment, behavior, and overall health. Among these, pediatric obstructive sleep apnea (OSA), insomnia, narcolepsy, and sleep-related movement disorders are the most clinically relevant conditions requiring targeted therapeutic strategies. Pediatric OSA, affecting approximately 2-5% of children, is characterized by recurrent upper airway obstruction during sleep and is associated with cognitive, behavioral, and cardiovascular consequences. Management is multimodal, with adenotonsillectomy as first-line therapy, which improves most patients, although residual disease remains common. Adjunctive treatments include anti-inflammatory therapies such as intranasal corticosteroids and leukotriene receptor antagonists, positive airway pressure therapy, and emerging approaches such as high-flow nasal cannula, drug-induced sleep endoscopy-guided surgery, orthodontic interventions, and hypoglossal nerve stimulation in selected populations. Insomnia in children is primarily managed with behavioral interventions, particularly cognitive behavioral therapy for insomnia (CBT-I) and parental education strategies. Melatonin has demonstrated modest efficacy in reducing sleep latency, especially in children with neurodevelopmental disorders, although long-term safety data remain limited. Narcolepsy requires a combination of behavioral and pharmacological management, with scheduled naps as first-line therapy and medications such as stimulants, sodium oxybate, and pitolisant targeting excessive daytime sleepiness and cataplexy. Sleep-related movement disorders, including restless legs syndrome and periodic limb movement disorder, are frequently associated with iron deficiency and are primarily treated with iron supplementation alongside behavioral strategies. Overall, the treatment of pediatric sleep disorders requires a multidisciplinary, individualized approach that integrates behavioral, pharmacologic, and interventional therapies. Advances in precision medicine, device-based treatments, and targeted interventions are expanding the therapeutic landscape, emphasizing the importance of early recognition and tailored management to improve long-term outcomes in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.